Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at and a replay will be accessible for 90 days following the presentation.

Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS).

"Dyne Therapeutics' FORCE Platform"

Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

"Dyne Therapeutics' Pipeline"

For more information, please visit , and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
ir@dyne-tx.com

Media
Stacy Nartker
781-317-1938